| Ytd | 14.44% | |
| 1y | -30.02% |
| Open | 3.12 | Prev Close | 3.12 | Low | 3.09 | High | 3.18 | Mkt Cap | 14.26M |
| Vol | 15.15K | Avg Vol | 50.65K | EPS | N/A | P/E | N/A | Forward P/E | -1.06 |
| Beta | 0.87 | Short Ratio | 2.39 | Inst. Own | 3.09% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-13 | 50-d Avg | 3.06 | 200-d Avg | 3.10 | 1yr Est | 4.57 |
BLRX News
BioLineRx Ltd. (BLRX) Q1 2026 Earnings Call Transcript
BioLine Rx (NASDAQ:BLRX) reported quarterly sales of $477.000 thousand which beat the analyst consen
- Announced first patient dosed in Phase 1/2a clinical trial of GLIX1 for treatment of glioblastoma
BioLineRx Ltd. (NASDAQ:BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company pursuing life-
TEL AVIV, Israel and OSLO, Norway, May 22, 2026 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE:
Management to Hold Conference Call at 8:30 a.m. EDT TEL AVIV, Israel, May 20, 2026 /PRNewswire/ -- B
BioLineRx shares new GLIX1 glioblastoma data showing anti-tumor activity, including in temozolomide-
GBM remains one of the most aggressive and treatment-resistant cancers, urgently in need of breakthr
New preclinical data further demonstrate GLIX1's robust efficacy in a dose-dependent manner, with st
The GLIX1 program is being conducted under a collaboration between BioLineRx and Hemispherian announ
Patient was dosed at NYU Langone Health under the supervision of Dr. Alexandra Miller, Chief of Neur
OSLO, Norway--(BUSINESS WIRE)--Hemispherian AS, a clinical-stage oncology company developing novel s
BioLineRx Ltd. (NASDAQ:BLRX) (TASE: BLRX), a clinical development stage biopharmaceutical company pu
GLIX1, a TET2 activator , is a first -in- class , oral, small molecule targeting DNA damage respons
BioLine Rx (NASDAQ:BLRX) reported quarterly losses of $(0.34) per share which beat the analyst conse
BioLineRx Ltd. (BLRX) Q4 2025 Earnings Call Transcript
BioLine Rx (NASDAQ:BLRX) reported quarterly sales of $194.000 thousand which missed the analyst cons
- On track to initiate Phase 1/2a clinical trial of GLIX1 for treatment of glioblastoma (GBM) by end
BioLineRx (NASDAQ: BLRX - Get Free Report) is expected to release its Q4 2025 results before the mar
BioLineRx Ltd. (NASDAQ: BLRX) to release Q4 earnings on March 23. Previous Q3 losses were 22 cents p
BioLineRx Ltd. (NASDAQ: BLRX) to release Q4 earnings on March 23. Previous Q3 losses were 22 cents p
Management to Hold Conference Call at 8:30 a.m. EDT TEL AVIV, Israel, March 16, 2026 /PRNewswire/ --
https://ir.biolinerx.com/static-files/e6f7cf56-4605-44e6-8ed9-f0738b67b983
BioLine Rx (NASDAQ:BLRX) reported quarterly losses of $(0.22) per share which beat the analyst conse
BioLineRx Ltd. ( BLRX ) Q3 2025 Earnings Call November 24, 2025 8:30 AM EST Company Participants Iri
- Establishes joint venture with Hemispherian AS to advance GLIX1, a first-in-class, oral, small mol
Management to Hold Conference Call at 8:30 a.m. EST TEL AVIV, Israel , Nov. 18, 2025 /PRNewswire/ --
Patent covers the use of GLIX1 for treating cancers in which cytidine deaminase (CDA) is not over-ex
BioLineRx Ltd. - Special Call Company Participants Irina Koffler - Managing Director Philip Serlin -
- GLIX1 restores TET2 activity in cancer, resulting in double stranded DNA breaks in cancer cells on
- GLIX1 restores TET2 activity in cancer, resulting in double stranded DNA breaks in cancer cells on
BioLineRx Ltd. (NASDAQ:BLRX ) Q2 2025 Earnings Conference Call August 14, 2025 8:30 AM ET Company Pa
BioLine Rx (NASDAQ:BLRX) reported quarterly losses of $(1.00) per share which beat the analyst conse
HC Wainwright & Co. analyst Joseph Pantginis reiterates BioLine Rx (NASDAQ:BLRX) with a Buy a